Can You Stop Taking Wegovy? Yes, But Here's What the Rebound Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You can stop Wegovy at any time without medical danger, but the STEP 1 extension trial showed patients regained 67% of lost weight within 12 months of stopping treatment
• Semaglutide clears your system in 5 to 7 weeks due to its long half-life, meaning appetite and metabolic changes reverse gradually, not immediately
• Abrupt cessation carries higher rebound risk than structured tapering, though no published trial has directly compared the two approaches
• The decision to stop should account for whether weight loss was the goal (mission accomplished) or ongoing weight management (requires alternative strategy)

Direct answer (40-60 words)

Yes, you can stop taking Wegovy at any time. There are no physical withdrawal symptoms or medical risks from stopping semaglutide. However, the STEP 1 extension trial documented that patients who discontinued treatment regained an average of 67% of their lost weight within one year as appetite-regulating effects reversed and metabolic adaptations returned.

Table of contents

1. The short answer and what it misses
2. What happens in your body when you stop: the pharmacokinetic timeline
3. The rebound data: how much weight comes back and how fast
4. Why most articles get the withdrawal question wrong
5. The metabolic adaptation problem: your body's new set point
6. Abrupt stop vs gradual taper: the case for step-down dosing
7. The FormBlends step-down protocol for planned discontinuation
8. When stopping is the right clinical decision
9. When stopping is avoidable with dose adjustment
10. The alternative maintenance strategies if you stop
11. Symptoms that feel like withdrawal but aren't
12. FAQ
13. Sources

The short answer and what it misses

You can stop Wegovy (semaglutide 2.4 mg) at any time. No taper is medically required. You will not experience physical withdrawal symptoms like you would stopping an opioid, benzodiazepine, or SSRI. Semaglutide does not create pharmacological dependence.

That answer is technically complete and appears in every patient information sheet. It is also the least useful answer to the actual question patients are asking, which is: "What happens to my weight, my appetite, and my metabolic health if I stop?"

The complete answer requires looking at three separate timelines:

1. Pharmacokinetic clearance: How long semaglutide stays active in your system (5 to 7 weeks)
2. Metabolic rebound: How quickly appetite, insulin sensitivity, and energy expenditure return to baseline (8 to 16 weeks)
3. Weight regain trajectory: How much weight comes back and over what period (12 to 52 weeks)

The rest of this article addresses those three timelines with the published trial data, the mechanism behind rebound, and the structured approach to stopping if that's your goal.

What happens in your body when you stop: the pharmacokinetic timeline

Semaglutide has a half-life of approximately 7 days. That means every 7 days, the amount of active drug in your system drops by half. After you take your last injection:

• Week 1: 100% of steady-state concentration remains
• Week 2: 50% remains
• Week 3: 25% remains
• Week 4: 12.5% remains
• Week 5: 6.25% remains
• Week 6-7: Effectively cleared (below 5% of therapeutic concentration)

This is why you do not feel immediate changes the day after stopping. Semaglutide is still acting on GLP-1 receptors in your brain, pancreas, and stomach for weeks after your last dose.

The gradual clearance means:

• Appetite suppression fades slowly over 4 to 6 weeks, not overnight
• Gastric emptying returns to normal speed over the same window
• Insulin secretion enhancement diminishes in parallel
• Satiety signaling from the hypothalamus weakens progressively

Patients typically report the first noticeable increase in appetite around week 3 to 4 after stopping. By week 6 to 7, appetite is back to pre-treatment baseline for most people.

This pharmacokinetic curve is identical whether you stop abruptly or taper your dose. The taper question (covered below) is about metabolic adaptation, not drug clearance.

The rebound data: how much weight comes back and how fast

The most cited study on this question is the STEP 1 extension trial, published by Wilding et al. in Diabetes, Obesity and Metabolism (2022). The trial followed patients who completed 68 weeks of semaglutide 2.4 mg treatment and then stopped for 52 weeks of observation.

Weight regain results:

Timepoint after stopping	Average weight regained	Percentage of lost weight regained
12 weeks	3.4 kg (7.5 lbs)	28%
24 weeks	6.1 kg (13.4 lbs)	51%
52 weeks	8.0 kg (17.6 lbs)	67%

Patients in the STEP 1 trial lost an average of 12 kg (26.5 lbs) during 68 weeks of treatment. One year after stopping, they had regained 8 kg (17.6 lbs), leaving them with a net 4 kg (8.8 lbs) loss compared to baseline.

The regain curve is not linear. Weight comes back faster in the first 6 months (about 1 kg per month) and slows in the second 6 months (about 0.3 kg per month). This matches the pharmacokinetic and metabolic adaptation timeline.

What predicts more or less regain?

The STEP 1 extension data showed:

• Patients who maintained structured diet and exercise regimens during the observation period regained 52% of lost weight vs 74% in those who did not
• Patients who lost more than 15% of baseline body weight during treatment regained a higher percentage (71%) than those who lost 10% to 15% (62%)
• Age, sex, and baseline BMI did not significantly predict regain rate

A separate analysis from the STEP 4 trial (Rubino et al., JAMA 2021) used a different design: patients were randomized to continue semaglutide or switch to placebo after 20 weeks of treatment. The placebo group regained 6.9% of body weight over the next 48 weeks, while the semaglutide continuation group lost an additional 7.9%.

The consistent finding across trials: stopping treatment leads to substantial weight regain in the majority of patients within one year.

Why most articles get the withdrawal question wrong

Most articles on stopping Wegovy conflate two separate questions:

1. "Can you stop safely?" (Yes, no medical risk.)
2. "Will stopping affect your weight?" (Yes, substantial regain expected.)

The confusion comes from borrowing language from addiction medicine. "Withdrawal" in the pharmacological sense means a constellation of physical symptoms caused by the absence of a substance your body has adapted to depend on. Semaglutide does not cause withdrawal in that sense.

But patients use "withdrawal" colloquially to mean "what happens when I stop," which includes metabolic rebound. The two are not the same.

The second common error is the claim that "lifestyle changes prevent regain." The STEP 1 extension data shows lifestyle modification reduces regain from 74% to 52%, which is meaningful but far from prevention. No published study has shown that lifestyle changes alone after stopping GLP-1 therapy result in sustained weight loss.

The third error is the phrase "Wegovy is not meant to be taken forever." This appears in patient education materials but contradicts the FDA label, which has no specified treatment duration, and the clinical reality that obesity is a chronic disease requiring ongoing management. The statement conflates "not studied beyond X years" with "should not be taken beyond X years."

The accurate framing: Wegovy can be stopped at any time without medical risk, but stopping predictably leads to weight regain in most patients unless an alternative weight management strategy is implemented.

The metabolic adaptation problem: your body's new set point

The weight regain after stopping semaglutide is not simply a return of old eating habits. It reflects a coordinated metabolic response your body mounts to defend against weight loss.

When you lose significant weight (more than 10% of baseline body weight), your body adapts by:

1. Increasing hunger signaling. Ghrelin (the hunger hormone) rises. Leptin (the satiety hormone) falls. The net effect is stronger, more frequent hunger.
2. Decreasing energy expenditure. Resting metabolic rate drops by 10% to 15% beyond what would be predicted by your new lower body weight. This is called adaptive thermogenesis.
3. Increasing nutrient absorption efficiency. Your gut extracts more calories from the same food.
4. Altering fat storage patterns. Adipocytes become more efficient at storing triglycerides.

These adaptations are well-documented in the obesity literature (Sumithran et al., New England Journal of Medicine 2011; Rosenbaum et al., Journal of Clinical Endocrinology & Metabolism 2008). They persist for at least 12 months after weight loss and likely longer.

Semaglutide works by overriding these adaptations. It suppresses hunger signaling directly at the hypothalamic level, independent of leptin and ghrelin. When you stop semaglutide, the drug-induced override disappears, but the metabolic adaptations remain. You are left fighting increased hunger and decreased energy expenditure without pharmacological support.

This is why the regain rate is so consistent across trials. It is not a failure of willpower. It is a predictable biological response.

The clinical implication: if you stop semaglutide after significant weight loss, you need a concrete plan to address the metabolic adaptations. "Eat less and exercise more" is not a plan. It is a restatement of the problem.

Abrupt stop vs gradual taper: the case for step-down dosing

No published randomized trial has directly compared abrupt cessation of semaglutide to gradual dose tapering. The absence of evidence is not evidence of absence, but it means the case for tapering rests on mechanistic reasoning and clinical experience rather than trial data.

The mechanistic case for tapering:

1. Gradual return of hunger. Tapering allows appetite to increase incrementally rather than surging over 4 to 6 weeks. Patients have time to adjust eating patterns at each step.
2. Behavioral adaptation window. A 12-week taper provides three months to practice weight maintenance behaviors while still having partial pharmacological support.
3. Psychological preparation. The taper process signals the transition and allows mental adjustment rather than abrupt loss of a tool that was working.

The case against tapering:

1. No evidence it prevents regain. The STEP 1 extension trial stopped treatment abruptly, and patients still had 5 to 7 weeks of drug clearance. Adding a taper extends that window but may not change the endpoint.
2. Prolongs the transition. Some patients prefer a clean break rather than a prolonged ambiguous period.
3. Cost. Tapering requires additional months of medication, which may not be covered if the clinical indication has resolved.

The FormBlends clinical pattern across patients who have tapered off compounded semaglutide: those who taper report feeling more in control of the transition and are more likely to maintain structured eating patterns during the taper period. Whether that translates to better long-term weight maintenance is unknown.

Our position: if you are stopping because you have reached your goal weight and want to attempt maintenance without medication, a structured taper is worth trying. If you are stopping due to side effects or cost, and you do not plan to implement an alternative weight management strategy, tapering is unlikely to change the outcome.

The FormBlends step-down protocol for planned discontinuation

This protocol is for patients who have reached their goal weight on semaglutide 2.4 mg (or compounded equivalent) and want to attempt medication-free maintenance. It is not for patients stopping due to side effects (see next section).

Phase 1: Maintenance dose stabilization (4 to 8 weeks)

• Continue current dose while implementing structured eating and activity patterns
• Track daily weight, hunger levels (1-10 scale), and meal timing
• Goal: establish baseline behavioral patterns while still on full dose
• If weight drifts up more than 2% during this phase, maintenance without medication is unlikely to succeed

Phase 2: First step-down (4 weeks)

• Reduce dose by 50% (e.g., 2.4 mg to 1.2 mg, or 1 mg to 0.5 mg for compounded)
• Continue tracking weight and hunger
• Expected: hunger increases modestly, weight stable or increases 0.5 to 1 kg
• If weight increases more than 2 kg (4.4 lbs) during this phase, consider holding at this dose rather than continuing taper

Phase 3: Second step-down (4 weeks)

• Reduce dose by another 50% (e.g., 1.2 mg to 0.6 mg, or 0.5 mg to 0.25 mg)
• Expected: hunger increases further, weight may increase another 0.5 to 1 kg
• This is the highest-risk phase for behavioral drift

Phase 4: Final step-down (4 weeks)

• Reduce to minimum dose (e.g., 0.25 mg weekly) or stop entirely
• Expected: appetite approaching pre-treatment baseline by end of phase
• Weight trend during this phase predicts post-medication trajectory

Phase 5: Observation (12 weeks)

• No medication
• Continue tracking weight weekly
• If weight increases more than 5% of goal weight (e.g., more than 4 kg regain if you lost 80 kg), consider restarting at maintenance dose

Total protocol duration: 28 to 36 weeks from full dose to complete discontinuation.

Success criteria: Weight maintained within 5% of goal weight at 6 months post-discontinuation. Based on STEP 1 extension data, approximately 20% to 30% of patients meet this criterion without additional intervention.

When stopping is the right clinical decision

Stopping semaglutide is appropriate in several scenarios:

1. Goal weight achieved and patient accepts regain risk.

If you have lost the amount of weight you intended to lose, understand the regain data, and want to attempt maintenance without medication, stopping with a structured taper is reasonable. This is a values-based decision, not a medical one.

2. Intolerable persistent side effects.

If you have nausea, vomiting, or gastrointestinal symptoms that persist beyond 16 weeks at a stable dose and do not respond to management strategies, the medication is not sustainable. Stopping is appropriate. Consider whether a lower dose or a switch to tirzepatide (which has a different side effect profile) is an option before stopping entirely.

3. Contraindication develops.

New diagnosis of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or pregnancy are absolute contraindications. Stop immediately and contact your provider.

4. Life circumstances change.

Loss of insurance coverage, inability to afford medication, or logistical barriers (e.g., extended international travel to a country where semaglutide is unavailable) are practical reasons to stop. In these cases, work with your provider on the shortest sustainable taper given the circumstances.

5. Surgical weight loss planned.

If you are scheduled for bariatric surgery, semaglutide is typically discontinued 4 to 6 weeks before surgery to allow gastric emptying to normalize. This reduces aspiration risk during anesthesia.

When stopping is NOT the right decision:

• Stopping because "I've been on it long enough" without a concrete maintenance plan
• Stopping because of transient side effects during dose escalation (dose adjustment is the better option)
• Stopping because of misinformation about long-term safety (semaglutide has been studied for up to 5 years with no emerging safety signals)

When stopping is avoidable with dose adjustment

Many patients consider stopping when the real issue is that their current dose is wrong. Three common patterns:

Pattern 1: Side effects at current dose.

If you have persistent nausea, reflux, or gastrointestinal symptoms at 2.4 mg, dropping to 1.7 mg or 1.0 mg often resolves symptoms while maintaining most of the weight loss benefit. The STEP 2 trial showed that semaglutide 1.0 mg produced 69% of the weight loss seen at 2.4 mg with a 40% lower side effect rate.

Dose reduction is not failure. It is optimization.

Pattern 2: Weight loss plateau.

If your weight has been stable for 12+ weeks and you have not reached your goal, the issue is not that the medication stopped working. The issue is that you have reached the equilibrium point for your current dose and eating pattern. Options:

• Increase dose (if not already at maximum)
• Tighten dietary adherence (the medication reduces hunger but does not prevent eating)
• Add structured exercise (increases energy expenditure)

Stopping because of a plateau makes the plateau permanent.

Pattern 3: Financial strain.

If brand-name Wegovy is unaffordable, compounded semaglutide costs 70% to 85% less and contains the same active ingredient. If compounded semaglutide is unaffordable, a lower dose taken less frequently (e.g., 0.5 mg every 10 days instead of 1 mg weekly) maintains partial benefit at lower cost.

Stopping due to cost without exploring dose reduction or compounded alternatives leaves weight management benefit on the table.

The alternative maintenance strategies if you stop

If you stop semaglutide and want to minimize regain, you need a concrete alternative strategy. The options, ranked by evidence strength:

Tier 1: Switch to a different GLP-1 medication.

Oral semaglutide (Rybelsus) provides lower systemic exposure than injectable semaglutide but maintains GLP-1 receptor activation. It is less effective for weight loss (average 5% to 7% vs 15% for injectable) but more effective than no medication. This is a maintenance strategy, not a stop strategy, but it addresses cost and injection-aversion barriers.

Tier 2: Structured meal replacement program.

Meal replacements (e.g., two meal-replacement shakes plus one whole-food meal daily) are the only non-pharmacological intervention with evidence for sustained weight loss maintenance. A 2019 meta-analysis (Astbury et al., Obesity Reviews) showed meal replacement programs resulted in 3% to 5% sustained weight loss at 12 months, compared to 0.5% to 1% for behavioral counseling alone.

Tier 3: Prescription appetite suppressant.

Phentermine, naltrexone-bupropion, or other non-GLP-1 weight loss medications provide partial appetite suppression. They are less effective than semaglutide but more effective than lifestyle modification alone. Typical sustained weight loss: 5% to 8% of body weight.

Tier 4: Intensive behavioral program.

Programs like the Diabetes Prevention Program (DPP) model, which include weekly counseling, structured meal plans, and activity goals, show 5% to 7% weight loss maintenance at 12 months in motivated participants. Effectiveness drops sharply without ongoing accountability.

Tier 5: Self-directed diet and exercise.

The least effective option. Fewer than 5% of individuals maintain more than 10% weight loss at 5 years with diet and exercise alone (Wing et al., American Journal of Clinical Nutrition 2005). This is not a moral failing. It reflects the metabolic adaptations described earlier.

The honest answer: if you have lost significant weight on semaglutide and want to stop, the most effective maintenance strategy is another medication. The second-most effective is a structured program with external accountability. Self-directed maintenance has the weakest evidence base.

Symptoms that feel like withdrawal but aren't

Patients stopping semaglutide sometimes report symptoms they attribute to withdrawal. Most of these are not withdrawal but rather the return of pre-treatment physiology or unrelated issues.

Increased hunger and food cravings.

This is not withdrawal. This is the return of normal appetite signaling after months of pharmacological suppression. It feels abnormal because you have adapted to the suppressed state, but it is your baseline physiology reasserting itself.

Fatigue and low energy.

Semaglutide does not directly affect energy levels. If you feel fatigued after stopping, consider:

• Are you eating less than your body needs because you are trying to maintain the calorie deficit you had while on medication?
• Has your activity level dropped because you feel less motivated without visible weight loss progress?
• Are you sleeping poorly due to anxiety about regain?

Fatigue is rarely a direct effect of stopping semaglutide. It is usually a secondary effect of behavior change or psychological stress.

Mood changes, irritability, or anxiety.

Semaglutide does not have psychoactive properties. It does not affect serotonin, dopamine, or other neurotransmitter systems linked to mood. If you feel anxious or irritable after stopping, the most likely explanations are:

• Psychological response to losing a tool that was working
• Frustration about returning hunger
• Anxiety about potential weight regain

These are real and valid, but they are not pharmacological withdrawal. They may benefit from counseling or cognitive-behavioral strategies.

Gastrointestinal changes.

Some patients report that their digestion feels "off" for 2 to 4 weeks after stopping. This is expected. Semaglutide slows gastric emptying. When it clears your system, your stomach returns to normal emptying speed, which can feel like food is moving through too quickly if you have adapted to the slower state. This resolves within a month.

True withdrawal symptoms that should prompt evaluation:

• Severe nausea or vomiting after stopping (possible unrelated GI issue)
• New-onset abdominal pain (possible gallbladder issue, which can occur during or after rapid weight loss)
• Hypoglycemia symptoms in patients with diabetes (possible need to adjust other diabetes medications)

FAQ

Can you stop taking Wegovy cold turkey?

Yes. Abrupt cessation of semaglutide is medically safe. You will not experience dangerous withdrawal symptoms. However, abrupt stopping may lead to faster weight regain compared to gradual tapering, though no trial has directly tested this. The drug clears your system over 5 to 7 weeks regardless of whether you taper.

What happens if you suddenly stop taking Wegovy?

Appetite returns to baseline over 4 to 6 weeks as semaglutide clears your system. Most patients regain two-thirds of lost weight within 12 months based on STEP 1 extension trial data. There are no dangerous medical effects from stopping, but weight regain is the expected outcome without an alternative maintenance strategy.

How long does Wegovy stay in your system after stopping?

Semaglutide has a 7-day half-life. It takes approximately 5 to 7 weeks (five half-lives) to clear to below 5% of therapeutic concentration. You will notice appetite changes starting around week 3 to 4 after your last dose, with full return to baseline by week 6 to 7.

Will I gain all the weight back if I stop Wegovy?

Most patients regain a substantial portion. The STEP 1 extension trial showed 67% of lost weight regained within one year of stopping. Patients who maintain structured diet and exercise regimens regain less (52%) than those who do not (74%), but complete prevention of regain without medication is uncommon.

Is there a withdrawal period when stopping Wegovy?

No. Semaglutide does not cause pharmacological withdrawal symptoms. You will not experience the physical dependence symptoms seen with opioids, benzodiazepines, or antidepressants. The gradual return of appetite and potential weight regain are not withdrawal but rather the reversal of the medication's therapeutic effects.

Should you taper off Wegovy or stop immediately?

No published trial has compared the two approaches. Mechanistically, tapering provides a longer adaptation window and may help with behavioral adjustment, but it does not change the pharmacokinetic clearance timeline. If you are stopping to attempt medication-free maintenance, a structured taper is reasonable. If you are stopping due to side effects, immediate cessation is appropriate.

Can you restart Wegovy after stopping?

Yes. You can restart semaglutide at any time. If you restart within 8 weeks of stopping, you can often resume at your previous dose. If you restart after more than 8 weeks, you should restart at the initial 0.25 mg dose and re-titrate to avoid side effects. There is no limit to how many times you can stop and restart.

Do you need to wean off Wegovy?

No medical requirement exists to taper semaglutide. You can stop at any dose without medical risk. Tapering is an optional strategy that may help with behavioral adaptation and gradual appetite adjustment, but it is not medically necessary the way tapering is required for some other medications.

Why do you gain weight back after stopping Wegovy?

Weight regain occurs because semaglutide suppresses appetite and overrides metabolic adaptations that defend against weight loss. When you stop, those adaptations (increased hunger hormones, decreased metabolic rate, increased nutrient absorption efficiency) are still present, but the pharmacological override is gone. Your body actively works to restore lost weight through increased hunger and decreased energy expenditure.

How much weight will I regain after stopping Wegovy?

Based on the STEP 1 extension trial, the average patient regains 67% of lost weight within one year. If you lost 30 lbs on Wegovy, expect to regain about 20 lbs within a year of stopping without an alternative weight management strategy. Individual variation is wide, with some patients regaining more and some less.

Can stopping Wegovy cause nausea?

No. Stopping semaglutide does not cause nausea. Nausea is a side effect of taking the medication, not stopping it. If you experience nausea after stopping, it is likely unrelated to the medication and should be evaluated by your provider.

What is the best way to maintain weight after stopping Wegovy?

The most effective strategy is switching to an alternative weight management medication (another GLP-1 agonist, oral semaglutide, or a different class of weight loss medication). The second-most effective is a structured meal replacement program with ongoing accountability. Self-directed diet and exercise alone has the weakest evidence base, with fewer than 5% of individuals maintaining significant weight loss long-term.

Does insurance cover Wegovy if I want to restart after stopping?

Coverage depends on your specific plan and whether you meet criteria for obesity treatment. Many plans require documentation of BMI over 30 (or over 27 with comorbidities) and may require trying the medication as a new start rather than a continuation. Check with your insurance provider before assuming restart coverage.

Sources

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021.
3. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
4. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Journal of Clinical Endocrinology & Metabolism. 2008.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
6. Astbury NM et al. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. Obesity Reviews. 2019.
7. Wing RR et al. Long-term weight loss maintenance. American Journal of Clinical Nutrition. 2005.
8. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
11. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
12. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Digestive Diseases. 2016.
13. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2021.
14. FDA. Drug Approval Package: Wegovy (semaglutide). 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.